Max Wattenberg

Has grant

Assistant Professor

Washington University in St. Louis

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Max Wattenberg is an Assistant Professor at Washington University in St. Louis, USA. His research areas encompass cancer immunotherapy, inflammation, and mechanisms of immune evasion, particularly in pancreatic cancer and hepatocellular carcinoma. Recent articles highlight his work on the roles of immune cells and systemic inflammation in cancer progression and treatment responses.

Recent Grants

Grant: Open

Investigating CD4+ T cell memory in cancer immunotherapy

Open Date: 2023-09-01

Close Date: 2028-08-31

Articles (9)

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

David M. Feldser

University of Pennsylvania

UNITED STATES

View details

Mito Tariveranmoshabad

University of Pennsylvania

UNITED STATES

View details

Gregory Beatty

Associate Professor

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Max Wattenberg

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (9)

Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.

A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

Collaborators (3)

David M. Feldser

Mito Tariveranmoshabad

Gregory Beatty

Make your next move.